Is EGCG a potential treatment for digestive system diseases like pancreatic cancer?

EGCG (epigallocatechin-3-gallate) is a natural compound found in green tea. In animal and lab studies, it has shown positive effects against several digestive system diseases, including pancreatic cancer ³. However, these are early findings, and EGCG is not currently a standard treatment for pancreatic cancer in humans. More research is needed to confirm its safety and effectiveness.

What the research says

A 2025 systematic review of animal studies found that EGCG has positive therapeutic effects on various digestive system diseases, including pancreatic cancer ³. The review included 63 studies with 738 animals, covering conditions like colorectal cancer, liver cancer, and pancreatic cancer ³. Another 2025 review highlights EGCG as one of several polyphenols with potent anticancer properties and minimal side effects in lab studies, but notes that clinical trials are still needed ⁹. A 2024 study tested a nanodrug containing EGCG along with gabapentin and pirfenidone in a mouse model of pancreatic cancer. This combination reshaped the tumor environment, increased immune cell infiltration, and nearly doubled survival time compared to controls ¹⁰. While these results are promising, EGCG has not been tested in large human trials for pancreatic cancer. Current standard treatments include chemotherapy regimens like FOLFIRINOX ⁵⁷, targeted therapies ¹, and surgery ², but EGCG is not part of standard care.

What to ask your doctor

• Are there any clinical trials testing EGCG or green tea extracts for pancreatic cancer?
• Could EGCG supplements interact with my current chemotherapy or other medications?
• What is the current evidence for natural compounds like EGCG in pancreatic cancer treatment?
• Should I consider any dietary changes, such as increasing green tea intake, as part of my care plan?